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Abstract: Periodontal disease (PDD) is associated with increased risk of cardiovascular disease, 
cerebrovascular disease, and mortality in many studies, while other studies have begun to suggest 
an association of  PDD with Alzheimer’s disease (AD). This paper discusses how infectious 
pathogens and systemic infection may play a role in AD. The roles of infection and inﬂ  amma-
tion are addressed speciﬁ  cally with regard to known AD pathologic lesions including senile 
plaques, neuron death, neuroﬁ  brillary tangles, and cerebrovascular changes. A testable model of 
proposed pathways between periodontal infection and AD is presented including three possible 
mechanisms: a) direct effects of infectious pathogens, b) inﬂ  ammatory response to pathogens, 
and c) the effects on vascular integrity. The role of gene polymorphisms is discussed, including 
apolipoprotein (APOE) ε4 as a pro-inﬂ  ammatory and pro-infection genotype.
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Periodontal disease (PDD) is associated with increased risk of vascular disease and 
mortality in more than 200 reports and reviews (eg, DeStefano et al 1993; Beck et al 
1996; Garcia et al 1998; Loesche et al 1998a, 1998b; Arbes et al 1999; Wu et al 2000; 
Grau et al 2004). Far fewer studies have examined the relationship between oral health 
earlier in life and Alzheimer’s disease (AD) in late life (Kondo et al 1994; Gatz et al 
2006; Kim et al 2007; Stein et al 2007). Inﬂ  ammation is recognized as a core process 
in atherosclerosis and cardiovascular disease (CVD), and may also have a major role 
in AD. Chronic inﬂ  ammation, as measured by blood inﬂ  ammatory markers (Table 1), 
is associated with increased risk for cognitive decline (Weaver et al 2002; Yaffe et al 
2003; Alley et al 2008) and dementia (Schmidt et al 2002; Engelhart et al 2004; Tan 
et al 2007). PDD is a common source of chronic systemic infection. This review sug-
gests mechanisms by which periodontal infection may promote AD. The proposed 
model gives a rationale for further experimental and clinical studies.
Research has documented declines in self-care and oral hygiene that occur in 
people with dementia (eg, Chalmers and Pearson 2005; Meurman and Hämäläinen 
2006). Our focus, however, is periodontal disease in early and midlife when it is clear 
that oral disease is an antecedent to dementia and when there would be no reason to 
suspect that dementia could have led to the oral disease.
Periodontal disease
PDD is a group of conditions that cause inﬂ  ammation and destruction of the gums, 
alveolar bone, and other structures that support the teeth. The etiology is complex 
involving the presence of pathogenic bacteria found in dental plaque and individual 
variation in host immune response. PDD is a common source of chronic systemic Neuropsychiatric Disease and Treatment 2008:4(5) 866
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infection in humans (Garcia et al 2000; Li et al 2000; 
Taylor et al 2006). The bacterial pathogens most strongly 
implicated in chronic periodontal disease are Porphyromonas 
gingivalis, Tannerella forsythensis, Treponema denticola, 
and Actinobacillus actinomycetemcomitans.
Elevated levels of interleukin 1 (IL-1) have been found 
in gingival crevicular ﬂ  uid (GCF) of patients with experi-
mentally induced gingivitis and active periodontal disease 
(Masada et al 1990; Kinane et al 1992). In patients with 
advanced periodontitis, substantial reduction of IL-1 levels 
occurred after treatment (Masada et al 1990). The simulta-
neous presence of p. gingivalis and t. forsythensis has been 
associated with increased GCF levels of inﬂ  ammatory media-
tors and associated with more severe disease (Airila-Mansson 
et al 2006). In gingivitis, inﬂ  ammatory mediators in the GCF 
do not penetrate deeply into tissues. Gingivitis advances to 
periodontitis when bacteria evade clearance by neutrophils 
and penetrate the deeper tissues (Offenbacher 1996).
Even low-grade infections in the oral cavity may be 
associated with moderate, sub-clinical systemic inﬂ  amma-
tory response indicated by blood elevations of C-reactive 
protein (CRP) and interleukin 6 (IL-6) (D’Aiuto and Tonetti 
2004; Taylor et al 2006). Severe PDD can induce chronic 
inﬂ  ammation and immune reactions that result in loss of 
bone and soft tissue that supports teeth in the jaws. Systemic 
inﬂ  ammatory markers are commonly elevated in individu-
als with PDD. In a recent review (Loos 2005), 8 studies 
showed that blood leukocytes and plasma levels of CRP were 
consistently higher in patients with periodontitis compared 
to healthy controls. In one study, carriers of common oral 
anaerobic bacteria had higher plasma levels of CRP (Bretz 
et al 2005). Furthermore, the severity of periodontal infection 
has been correlated with serum levels of inﬂ  ammatory mark-
ers. For example, in the Atherosclerosis Risk in Communities 
study (ARIC), older adults with more extensive periodontal 
pockets had one-third higher plasma CRP than those with 
mild PDD (Slade et al 2003). Other inﬂ  ammatory proteins 
such as IL-6 and tumor necrosis factor alpha (TNF-α) have 
been found to be elevated in advanced PDD. For example, 
individuals with extensive PDD had 2- to 4-fold higher mean 
plasma levels of IL-6 and TNF-α than those with mild or no 
disease (Bretz et al 2005).
The success of reducing CRP and other inﬂ  ammatory 
markers with periodontal treatment has been mixed. Inter-
vention studies of moderate to severe PDD use standard 
therapeutic scraping of dental calculus (scaling and root 
planing) alone or in combination with antiinﬂ  ammatory or 
antiinfective drugs. Scaling and root planing alone reduced 
CRP levels in one study (D’Aiuto and Tonetti 2004) but did 
not reduce CRP, interleukins, or TNF-α in two other studies 
(Fokkema et al 2003; Ide et al 2003). Use of antiinﬂ  amma-
tory drugs in combination with scaling and root planing 
reduced CRP and haptoglobin in one study (Ebersole et al 
1997) and in another study antiinfective drugs in combina-
tion with scaling and root planing reduced CRP, especially 
among those with elevated baseline CRP (Mattila et al 2002). 
Extraction of all teeth in advanced PDD patients caused a 
reduction in blood CRP, ﬁ  brinogen, white cells, platelets, 
and plasminogen activator inhibitor-1 in another study 
(Taylor et al 2006). Though the most effective treatment for 
reduction of inﬂ  ammation in PDD remains unclear, treat-
ment of periodontal infection may help to reduce systemic 
inﬂ  ammation.
PDD has been associated with increased risk of mortal-
ity, cardiovascular disease, and stroke in a large number of 
studies. For example, in the National Health and Nutrition 
Examination Study (NHANES), a large US national sample, 
adults with periodontitis had a 46% increased risk of inde-
pendent all-cause mortality and a 25% increased risk of 
coronary heart disease (DeStefano et al 1993). Other studies 
have shown that individuals with markers of poor oral health 
Table 1 Inﬂ  ammatory markers associated with cognitive decline 
and dementia in epidemiological studies
Cytokines Associated with
Interleukin 1 (IL-1) Dementia (Framingham Study1)
Interleukin 6 (IL-6) Cognitive Decline (MacArthur Studies2; 
Health ABC Study3)
Dementia (Rotterdam Study4)
Interleukin 10 (IL-10) Cognitive Decline (Leiden 85 + Study5)
Tumor necrosis factor 
alpha (TNF-α)
Cognitive Decline (Leiden 85 + Study5)
Dementia (Framingham Study1)
Acute Phase Proteins
C-reactive protein (CRP) Cognitive Decline (Health ABC Study3; 
Greek Community6)
Dementia (Rotterdam Study4; 
Honolulu-Asia Aging Study7)
α-1 antichymotrypsin (ACT) Cognitive Decline (Longitudinal Aging 
Study Amsterdam8)
Dementia (Rotterdam Study4)
Cell Adhesion Molecules
Intercellular adhesion 
molecule (ICAM-1)
Cognitive Decline (Greek Community6)
Vascular cell adhesion 
molecule (VCAM-1)
Cognitive Decline (Greek Community6)
Notes: 1Tan et al 2007;   2Weaver et al 2002;   3Yaffe et al 2003;   4Engelhart et al 2004; 
5van Exel et al 2003; 6Dimopoulos et al 2006; 7Schmidt et al 2002; 8Dik et al 2005.Neuropsychiatric Disease and Treatment 2008:4(5) 867
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are at 2 to 4 times greater risk for stroke (Beck et al 1996; 
Loesche et al 1998b; Wu et al 2000; Grau et al 2004).
Severity of PDD has shown a dose-response relationship 
with disease outcomes and mortality (Loesche et al 1998a; 
Arbes et al 1999). A longitudinal dental study of veterans 
found that individuals with the deepest probing pocket depths 
and the greatest degree of alveolar bone loss had the highest 
independent mortality risk (Garcia et al 1998). Though not all 
studies have supported PDD as a risk for CVD and cerebro-
vascular disease, most reports support a modest relationship 
(see Scannapieco et al 2003 for a systematic review).
PDD may also be associated with increased risk for AD. 
In Swedish twins, Gatz and colleagues (2006) found that 
those who had lost half or more of their teeth before age 35 
had a 1.7-fold greater risk for AD, after controlling for other 
factors. Within a twin pair, the demented twin was four times 
more likely to have had worse oral health before age 35. 
Similarly, a case control study of AD in Japan found that 
loss of more than half of adult teeth by age 50–60 increased 
AD risk by 2.6-fold (Kondo et al 1994). In this study, PDD 
occurring 20–30 years prior to dementia onset was the most 
frequent cause of tooth loss. In a study of 144 nuns, having 
few or no teeth predicted a 4.3-fold higher risk of dementia, 
but only among those who did not carry the apolipoprotein 
(APOE) ε4 allele (Stein et al 2007). The study included dental 
records that indicated whether teeth were lost due to PDD 
or other causes. In a Korean community population, persons 
with fewer teeth were at 1.6-fold greater risk of dementia 
in subsequent years if they did not have their missing teeth 
replaced by dentures (Kim et al 2007). Teeth are commonly 
lost as a result of periodontal infection and dental caries, both 
of which are caused by exposure to bacteria. Less commonly, 
teeth are lost due to trauma. Studies that measure markers of 
periodontal infection, not just tooth loss, will be important to 
establishing whether oral health may be related to AD.
Systemic infection: From mouth 
to bloodstream
The mouth is a primary channel by which external organisms 
enter the body. Transient bacteremia occurs after tooth brushing 
and ﬂ  ossing as well as after normal dental procedures (Loos 
2005; Forner et al 2006). In individuals with good oral and 
immune health, the transient bacteremia has few consequences. 
It is suspected that individuals with periodontal infection have 
higher levels of pathogenic accumulation and may experience 
transient bacteremia multiple times per day (Li et al 2000; 
Loos 2005; Forner et al 2006). Gram-positive and Gram-
negative oral bacteria contain several components within 
their membranes that can induce pro-inﬂ  ammatory cytokines 
including IL-1, IL-6, and TNF-α. Lipopolysaccharide (LPS) 
endotoxin is the most often studied of these bacterial compo-
nents (Beck et al 1996; Wilson et al 1996).
The oral cavity has several barriers, physical, electrical, 
and chemical, that inhibit penetration by pathogens. First, the 
surface epithelium tissue layer provides a physical barrier 
composed of tight junctions and a chemical barrier contain-
ing peptide antibiotics called defensins. An electrical barrier 
affects the ﬂ  ow of electrons between the oral cavity and 
microbes that are introduced. The high reduction potential in 
the oral cavity increases oxidation of local bacteria. Another 
layer of protection is an immunological layer of antibody-
forming cells. Finally, the reticuloendothelial system protects 
through phagocytosis to engulf and destroy bacteria upon 
entry into the blood (Weinberg et al 1998; Loesche and 
Lopatin 2000). If these barriers are compromised by PDD, 
trauma, or immune suppression, microbes can disseminate to 
cause acute or chronic infection (Li et al 2000). Once in the 
bloodstream, these bacteria can induce acute phase response 
characterized by increased white blood cell counts and the 
release of inﬂ  ammatory cytokines.
Supragingival plaque, above the gums, contains dense 
layers of Gram-positive bacteria (see Figure 1). If these 
bacteria penetrate the epithelium, they may survive the 
oral cavity barriers and enter the bloodstream (Loesche and 
Lopatin 2000). Though not speciﬁ  cally associated with PDD, 
the number of these bacteria increase in conditions of poor 
oral hygiene and may leak into the blood and result in the 
inﬂ  ammation of distant systems.
Subgingival plaque, below the gums, contains primarily 
Gram-negative organisms in individuals with disease 
(Loesche and Lopatin 2000). These get trapped in the space 
between the tooth and the gum tissue and provoke local 
inﬂ  ammatory responses giving rise to PDD. PDD is charac-
terized by chronic Gram-negative infection in which bacteria 
may enter the bloodstream via the epithelium. Ulcerations 
in the gingival epithelium allow bacteria to spread from the 
pocket between the tooth and gum into the capillaries of 
the epithelium and thus into systemic circulation. Bacterial 
endotoxin (LPS contained in bacterial cell membranes) may 
enter the bloodstream. In PDD, the large surface area of the 
pockets allows a larger degree of LPS endotoxin to enter 
compared to the intact endothelial lining and more limited 
pockets in individuals without disease. LPS induces cyto-
kine production and its entry may alter blood coagulation 
and promote atherosclerosis and thrombogenesis (Valtonen 
1991; Stoll et al 2004). Cytokines produced locally, for Neuropsychiatric Disease and Treatment 2008:4(5) 868
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example in the periodontium, are generally degraded locally. 
However, under conditions of repeated challenge, cytokine 
receptors may become saturated and less able to eliminate 
cytokines, thus allowing them to “spill over” into systemic 
circulation affecting serum levels of cytokines and acute 
phase reactants (Offenbacher 1996). Chronic periodontal 
infection continuously attracts circulating leukocytes to 
inﬂ  amed periodontal tissues keeping immune cells activated 
(Fokkema et al 2003).
Bacteria are not the only pathogens that are likely to enter 
the system when defenses are vulnerable. Viruses are fre-
quently detected in periodontal pockets (Kubar et al 2005). 
In one study of 30 patients with advanced periodontitis, 78% 
had at least one of ﬁ  ve viruses and 40% were co-infected 
with two to ﬁ  ve viruses (Parra and Slots 1996), particularly 
herpes viruses including cytomegalovirus (CMV), Epstein-
Barr virus (EBV), and herpes simplex virus (HSV) found 
in 60%, 30%, and 20% of patients, respectively. Herpes 
viruses also infect inflammatory cells in periodontitis 
(Contreras et al 1999). The potential role of bacterial and 
viral pathogens in AD pathogenesis is discussed in more 
detail below.
Transmigration from bloodstream 
to brain
Though the blood–brain barrier (BBB) generally prevents 
entry of substances into the brain, there is evidence that 
inﬂ  ammatory cytokines can enter or inﬂ  uence the brain under 
certain circumstances. For example, IL-6 and certain other 
blood cytokines elevated during the acute phase response 
enter the brain to initiate sickness behaviors including fever, 
malaise, reduced appetite, and decreased social contact (Perry 
2004). These behaviors are a normal response that is adap-
tive to conserve energy stores when ﬁ  ghting infection and 
possibly protect others from the spread of disease. IL-6 and 
other cytokines may be transported across the intact BBB 
through speciﬁ  c transport processes (Pan and Kastin 1999; 
Banks et al 2002). IL-6 and other cytokines may also enter 
through fenestrated capillaries in circumventricular organs 
(including the pineal gland, vascular organ of the lamina 
terminalis, area postrem, and subfornical organ) near the 
base of the brain that are outside the BBB and are more easily 
penetrated (Banks et al 2002; Perry 2004).
Infectious pathogens and AD
Exposure to infectious pathogens of various types is a pos-
sible risk factor for AD, although mixed results allow only 
tentative conclusions (Balin and Appelt 2001; Holmes et al 
2003; Itzhaki et al 2004; Kinoshita 2004; Little et al 2004; 
Mattson 2004; Ringheim and Conant 2004; Robinson et al 
2004; Wozniak et al 2005). Research has focused primarily 
on the bacterium Chlamydia pneumoniae, and herpes viruses 
including HSV and CMV. Very few studies have reported 
investigating the presence oral disease-related bacteria in 
AD (eg, Riviere et al 2002).
C. pneumoniae infection is characterized by chronic 
inﬂ  ammation and is generally acquired orally or nasally. 
Although some studies found C. pneumoniae in post-mortem 
AD brains (Balin and Appelt 2001), other labs failed to rep-
licate these results (Nochlin et al 1999; Gieffers et al 2000; 
Ring and Lyons 2000; Wozniak et al 2003). C. pneumoniae 
antigens have been located in microglia and astroglia cells 
in brain regions with AD neuropathology (Itzhaki et al 
2004). An in vitro cell model of the BBB showed the pos-
sibility that C. pneumoniae could enter the brain (MacIntyre 
et al 2003). In other studies that have not been replicated, 
infective C. pneumoniae was obtained postmortem from an 
ulcerated
pocket
(to blood stream) 
Gingiva
Plaque
Tooth
gram  positive
gram  negative
(supraginginval)
(subgingival)
bacteria
bacteria
Figure 1 In periodontal disease, the gingiva recedes from the tooth forming pockets 
through which bacteria may more easily enter the bloodstream.Neuropsychiatric Disease and Treatment 2008:4(5) 869
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AD brain and induced amyloid plaques in a mouse model 
(Little et al 2004).
Treponema bacteria, a family of Gram-negative spiro-
chetes commonly associated with PDD, was found in the 
brains of AD patients with greater frequency than in non-AD 
controls (Riviere et al 2002). The AD patients also had a 
greater variety of treponema species. The levels of bacte-
ria measured in the blood did not differ between the AD 
patients and controls suggesting that AD subjects may be 
more susceptible to infection in the central nervous system 
(CNS) than controls. Antigens for two types of treponema 
were found in the trigeminal ganglia, pons, and hippocampus 
possibly indicating that the bacteria reached the brain via the 
trigeminal nerve. Other spirochetes have been found in the 
brain tissue, blood, and cerebrospinal ﬂ  uid of AD patients 
(Miklossy 1993), however the ﬁ  nding was not conﬁ  rmed 
in another study (McLaughlin et al 1999) and the link of 
spirochete presence to AD has been treated with skepticism 
(Hammond et al 1993).
Viral infection may also be a risk factor for AD, par-
ticularly herpes viruses. Nondemented older adults with 
high serum levels of antibodies for CMV had faster rates of 
cognitive decline over a four year period than those with low 
levels of CMV antibodies (Aiello et al 2006). HSV-1 is found 
in a high proportion of non-AD elderly brains (Jamieson 
et al 1992) and is most often not found to be associated 
with dementia. This does not preclude the role of HSV in 
AD, because presence of a virus is not sufﬁ  cient to result in 
disease. Individual factors such as immune function, patho-
gen virulence, and genetic factors determine the outcome 
of exposure to a virus. Latent viruses may be reactivated 
by immunosuppression, stress, or inﬂ  ammation in the brain 
(Itzhaki and Wozniak 2007). In AD brains, HSV-1 is present 
in areas of AD neuropathology. Remarkably, APOE ε4 allele 
carriers showed more than 15-fold risk of AD in the presence 
of HSV-1 in this sample. The APOE alleles may affect the 
degree or recurrence of viral damage, rather than susceptibil-
ity to infection with the virus (Itzhaki et al 1997; Itzhaki and 
Wozniak 2006). HSV-1 may contribute to the formation of 
amyloid plaques and abnormally phosphorylated tau protein, 
possibly by attenuating the processing of amyloid precursor 
protein (APP) into the toxic Aβ-peptide (Shipley et al 2005; 
Itzhaki and Wozniak 2007).
Infection with viruses early in life may put individuals 
at risk of becoming re-infected throughout life, even chroni-
cally (Robinson et al 2004). Since AD develops later in life, 
it is hypothesized that pathogens acquired early in life are 
not expressed until decades later. Age-related decline in 
immunity against pathogens or a long period of pathogen 
latency may offer explanations for the effects of pathogens 
found in older adulthood and rarely found in younger people 
(Itzhaki et al 2004; Robinson et al 2004). Systemic infec-
tion may result in the entry of cytokines into the brain and 
inﬂ  ammation that reactivates latent HSV, further enhancing 
damage (Itzhaki and Wozniak 2006).
Viruses may infect multiple sites throughout the body 
including the periodontium and the brain without requiring 
a direct relationship between the different sites. It remains 
possible that PDD and AD are both partially, but indepen-
dently, inﬂ  uenced by viruses.
Inﬂ  ammation and AD
Inﬂ  ammatory markers appear to be higher in persons with 
AD than normal age-matched controls. Blood IL-6 (Singh 
and Guthikonda 1997) and α1-antichymotrypsin (ACT) 
levels (Licastro et al 1995) are elevated in some AD patients 
compared to controls. In the brain, acute phase proteins 
IL-1, IL-6, S-100, CRP, and α2-macroglobulin are elevated 
in the temporal cortex of AD patients compared to controls 
(Grifﬁ  n et al 1989; Wood et al 1993; McGeer et al 1994). 
CRP and serum amyloid P are localized to the characteristic 
AD extracellular amyloid deposits and neuronal tau protein 
aggregates post-mortem (Kalaria 1992; Duong et al 1997). 
Microvessels from AD brains release 60% to 88% more 
IL-1β, IL-6, and TNF-α than non-AD controls (Grammas 
and Ovase 2001). Though some AD patients have elevated 
systemic inﬂ  ammatory markers, it is not clear whether 
systemic inﬂ  ammation precedes dementia or if neuroin-
ﬂ  ammation itself might result in systemic inﬂ  ammation. 
Longitudinal studies, discussed below, suggest that elevated 
systemic inﬂ  ammation predicts dementia months to years 
later; however, neurological changes can precede clinical 
signs of dementia by more than a decade.
In community based samples, elevated blood inﬂ  am-
matory markers predict risk for dementia and incidence of 
cognitive impairment (Schmidt et al 2002; Engelhart et al 
2004; Tan et al 2007; Alley et al 2008). In the Rotterdam 
Study, elevated blood IL-6, CRP, and ACT predicted 
increased risk of dementia onset over a year later (Engelhart 
et al 2004). Over a follow-up period of 25 years, men in the 
Honolulu-Asia Aging Study had a 3-fold increased risk for 
dementia in the top quartiles of inﬂ  ammatory markers versus 
the lowest quartile at midlife (Schmidt et al 2002). In indi-
viduals with AD, elevated IL-1β predicted rates of cognitive 
decline (Holmes et al 2003). Patients with elevated markers 
preceding a baseline exam showed a greater rate of cognitive Neuropsychiatric Disease and Treatment 2008:4(5) 870
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decline over a two-month follow-up period than those who 
did not have elevated levels prior to baseline. Though high 
levels of inﬂ  ammatory markers predict dementia risk and 
cognitive decline in the demented, they may not be associated 
with decline in those with higher levels of normal cognitive 
function (Dik et al 2005; Alley et al 2008). For example, Dik 
and colleagues (2005) found that ACT was associated with 
declines in mental status, but not with measures of memory, 
ﬂ  uid intelligence, or information processing speed.
Model of proposed mechanisms 
for an association between 
periodontal infection and AD
This model proposes possible links between oral infection 
and the pathology of AD. We do not claim that oral infection 
or inﬂ  ammation are the causes of AD, rather we propose that 
they may contribute to, exacerbate, and share risk factors 
with AD. Pathogenic bacteria in the oral cavity can lead to 
periodontal infection. Individuals vary in susceptibility to 
infection, partly due to the state of their oral hygiene and 
possibly due to particular genotypes that are more vulner-
able to infection and have elevated inﬂ  ammatory responses 
(discussed in more detail below). Once bacteria and/or 
viruses enter the blood stream, the infection may become 
systemic. From systemic circulation, pathogens and their 
products may cross the BBB and enter the brain. This may 
contribute to the development of AD pathology through three 
interrelated processes (see Figure 2). They are the direct 
effects of pathogenic products, the inﬂ  ammatory response to 
these pathogens, and the effect on vascular integrity. These 
processes have been demonstrated to impact microglial acti-
vation, the production and formation of amyloid beta (Aβ) 
and tau protein, and cerebrovascular pathology. Microglial 
activation is associated with neuron death in AD though the 
causal direction remains undetermined. Aβ and tau proteins 
are central contributors to inter-related AD pathologies, 
plaques and neuroﬁ  brillary tangles.
Pathogen products
The cell walls of Gram-negative bacteria contain LPS that 
induces a number of host defenses. LPS stimulates certain 
inﬂ  ammatory cytokines that are associated with microglial 
activation and altered processing of APP (Brugg et al 1995; 
Mattson 2004). Animal studies show that chronic infusion of 
LPS into rat brains may result in long lasting inﬂ  ammatory 
reaction with pathological changes. These changes include an 
increased number of activated astrocytes, increased number 
and density of reactive microglia, increase in IL-1β, TNF-α, 
and beta amyloid precursor protein (βAPP), the degeneration 
of hippocampal pyramidal neurons, impairment in spatial 
working memory, and decreased size of hippocampus and 
temporal lobe associated with increased lateral ventricles 
(Hauss-Wegrzyniak et al 2000).
Viruses could also contribute directly to AD pathology. 
HSV has glycoproteins that are very similar in amino acid 
sequences to Aβ and tau protein and may aggregate like 
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Figure 2 Proposed pathways between periodontal infection and Alzheimer’s disease pathology.
Abbreviations: LPS, lipopolysaccharide; APP, amyloid precursor protein; AB, amyloid beta; NFTs, neuroﬁ  brillary tangles.Neuropsychiatric Disease and Treatment 2008:4(5) 871
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Aβ (Cribbs et al 2000; Takakuwa et al 2001). HSV may also 
impact the processing of APP (Benboudjema et al 2003). For 
example, Shipley and colleagues (2005) reported that HSV-1 
and HSV-2 infection of neuronal cells in vitro caused rapid 
decreases in cell levels of full length APP. The production 
of Aβ may be increased as a result of altered APP processing 
or may also result directly from HSV infection (Satpute-
Krishnan et al 2003; Itzhaki and Wozniak 2006).
Inﬂ  ammation
It is clear that inﬂ  ammation is involved in AD. However, it 
is not yet clear if inﬂ  ammatory processes initiate pathologi-
cal processes or merely contribute to disease progression. 
There are several mechanisms through which systemic 
inﬂ  ammation might contribute to pathogenesis in AD. These 
include the priming of microglia, dysregulation of APP and 
Aβ processing and metabolism, the activation of microglia 
in response to Aβ, and a neurotoxic loop or vicious cycle in 
which immune response intended to be neuroprotective leads 
to exacerbation of the process.
The presence of primed microglia may inﬂ  uence the 
response of the brain to systemic infection. In aging indi-
viduals, changes in glia can cause exaggerated inﬂ  ammatory 
responses (Licastro et al 2005). It is hypothesized that in AD 
and other neurodegenerative diseases, microglia become acti-
vated, leading to higher production of inﬂ  ammatory mediators 
and chronic overreaction to subsequent stimuli (Marx et al 
1998; Perry 2004). Microglia release many inﬂ  ammatory 
mediators in the brain including acute phase proteins, comple-
ment factors, prostaglandins, free radicals, and cytokines 
(Perry 2004). Aβ peptides in the brain may also potentiate 
monocyte transmigration from blood to brain (Brod 2000).
The processing and metabolism of APP and Aβ is critical 
in AD pathogenesis (Blasko and Grubeck-Loebenstein 2003; 
von Bernhardi et al 2007). In AD, this balance is dysregu-
lated. Aβ is aggregated as oligomers and ﬁ  brils which have 
varying neurotoxicity (Klein et al 2001). Systemic inﬂ  am-
mation and cytokine production can augment the regulation 
of APP and Aβ, though the effects are complex and may 
depend on which combination of mediators is present (Marx 
et al 1998; Blasko and Grubeck-Loebenstein 2003; Dziedzic 
2006; Heneka and O’Banion 2007).
Grifﬁ  n and colleagues (1998) proposed that IL-1 is critical 
to the processing of βAPP, favoring continued Aβ deposition 
and the cyclical continuation of inﬂ  ammatory response and 
cytokine overexpression. TNF-α and interferon gamma in 
combination also alter the metabolism of βAPP, trigger 
Aβ peptide production, and inhibit soluble APP secretion 
(Blasko et al 1999). IL-1 stimulates APP synthesis and factors 
that lead to its amyloidogenic properties (Schmitt et al 1996), 
contributes to the phosphorylation of tau protein favoring 
tangle formation, increases production of nitric oxide synthase 
fatal to cells, and increases the production of acetylcholines-
terase responsible for the breakdown of acetylcholine which 
is important in learning and memory function (Mrak and 
Grifﬁ  n 2005). Beta secretase, a protease that cleaves APP 
and results in toxic Aβ peptides, may also be upregulated by 
inﬂ  ammatory mediators (Heneka and O’Banion 2007). In 
mice with APP gene mutations, systemic administration of 
LPS resulted in altered expression and processing of APP and 
increased production of Aβ (Sheng et al 2003). Mice with this 
gene mutation generate high levels of amyloidogenic Aβ.
Aβ and its aggregation trigger the activation of microg-
lial cells which respond by producing acute-phase proteins, 
complement components, prostaglandins, and cytokines 
some of which are neurotoxic or contribute to aggregation 
by stimulating Aβ production. This response may be more 
injurious than the plaques and tangles to which inﬂ  amma-
tory processes are responding, resulting in neural damage 
and death (McGeer and McGeer 1995; Marx et al 1998; 
Neuroinﬂ  ammation Working Group 2000; Wilson et al 2002; 
Blakso and Grubeck-Loebenstein 2003; Bate and Williams 
2004; D’Andrea et al 2004; Nagele et al 2004; Dziedzic 2006; 
von Bernhardi et al 2007).
Nonspeciﬁ  c responses of phagocytic cells can remove Aβ 
deposits, as well as recruit more microglia which produce 
more immune mediators. Cell attempts to dissolve plaques 
and tangles may cause toxicity via the release of neurotoxic 
substances including nitric oxide and other reactive oxygen 
species (Marx et al 1998; Heneka and O’Banion 2007). Pro-
inﬂ  ammatory cytokines including IL-6 and TNF-α can be 
directly toxic in high concentrations or can stimulate further 
Aβ production, aggregation, and toxicity (Marx et al 1998; 
Brod 2000; Blakso and Grubeck-Loebenstein 2003; Perry 
2004; Heneka and O’Banion 2007). Chronic inﬂ  ammation 
may result in chronic acute-phase protein secretion which 
favors the formation of Aβ ﬁ  brils. This ﬁ  brillar conformation 
of Aβ may be important in its ability to induce inﬂ  ammation 
(Blasko and Grubeck-Loebenstein 2003). Over sustained 
periods of time, these products may contribute to neurodegen-
eration via injury of surrounding noninfected cells resulting 
in neuron loss (Rogers et al 2002).
Vascular changes
Oral bacteria including Streptococcus sanguis and 
P. gingivalis have been shown to result in the expression Neuropsychiatric Disease and Treatment 2008:4(5) 872
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of platelet aggregation proteins that may play a role in the 
formation of atheromas and thrombi possibly contributing to 
vascular disease (Herzberg and Meyer 1996, 1998; Sharma 
et al 2000; Pham et al 2002). High levels of atherosclerosis 
have been found to increase the risk of cognitive decline 
independent of other factors (Haan et al 1999). Furthermore, 
the presence of inﬂ  ammatory cytokines in the blood increases 
platelet aggregation in cerebral blood vessels which can lead 
to atherogenesis and thrombus formation associated with 
strokes and hypoperfusion.
Vascular changes in the brain may also contribute to the 
formation of AD pathology. Platelets are a primary source of 
APP (Bush et al 1990; Chen et al 1995; Zandi and Breitner 
2001) and platelet aggregation associated with cerebrovascu-
lar pathology may increase the production of Aβ in the brain. 
In endothelial cells, Aβ causes the secretion of inﬂ  ammatory 
proteins which upregulate the production of APP (Grammas 
and Ovase 2001).
Possible role of genes in infection 
and inﬂ  ammation
Acquisition of infectious disease requires the presence of both 
a pathogen and a susceptible host. The expression of disease 
depends on virulence of the pathogen and immune response 
of the host to the pathogen (Beck et al 2000). Periodontal 
researchers (Beck et al 1996) hypothesize a hyperinﬂ  amma-
tory phenotype that causes some individuals to have exag-
gerated inﬂ  ammatory reactions in response to pathogens. 
Particular alleles in the HLA-DR3/4 or -DQ system are 
suspected to produce exaggerated inﬂ  ammatory responses 
to infection. Carriers have peripheral blood monocytes that 
secrete 3- to 10-fold greater amounts of inﬂ  ammatory media-
tors in response to LPS. For example, patients with refrac-
tory periodontitis, a condition in which oral health does not 
improve despite treatment and proper hygiene, release higher 
levels of IL-1β and prostaglandin-E2 than patients with non-
refractory periodontitis (Hernichel-Gorbach et al 1994).
Polymorphisms for genes involved in inflammatory 
process are a logical target for exploration in understand-
ing a possible common cause or link between periodontal 
disease and Alzheimer’s disease. Several candidate genes 
have been proposed that may potentially link PDD and CVD 
(Kornman et al 1999; Kornman and Duff 2001; Goteiner et al 
2008). While no publications have directly considered gene 
polymorphisms common to PDD and AD, IL-1 and TNF-α 
polymorphisms have been associated with both diseases 
(Diehl et al 1999; Galbraith et al 1999; Grimaldi et al 2000; 
Nicoll et al 2000; McCusker et al 2001; Raneiro et al 2004). 
Not all studies have conﬁ  rmed these associations (Craandijk 
et al 2002; Folwaczny et al 2004; Donati et al 2005) and more 
research on genetic polymorphisms is needed to explain 
discrepant ﬁ  ndings (Loos et al 2005).
The APOE ε4 allele is implicated in susceptibility to 
infection or the degree of resulting damage from viruses 
(Itzhaki et al 1997; Lin et al 1998, 2001; Wozniak et al 2005). 
AD brains positive for HSV were 17 times more likely to 
carry the APOE ε4 allele compared to HSV-negative non-
AD brains suggesting that the combination of an APOE ε4 
allele and HSV may confer higher risk for AD than either 
alone (Itzhaki et al 1997).
APOE ε4 alleles may also play a role in inﬂ  ammatory 
response to infection. For example, mice with APOE ε4 
genotypes have greater elevations of inﬂ  ammatory cytokines 
in systemic circulation and in the brain in response to LPS 
than those with APOE ε3 (Lynch et al 2003). The ability 
of astroglial cells to phagocytize Aβ may also depend on 
APOE type (Heneka and O’Banion 2007). ApoE and other 
genetic markers of hyperinﬂ  ammatory response could be 
used to identify individuals at risk for targeted prevention 
and treatment.
Establishing a relationship
Many more studies are needed to validate an association 
between periodontal disease and dementia, including 
prospective studies that directly measure oral microbiol-
ogy. Several requirements must be met before a causal 
relationship between PDD and AD can be established. 
First, PDD must precede dementia. Among the few longi-
tudinal or archival studies that have reported tooth loss as 
a risk factor for dementia, two have measured periodontal 
disease as a possible cause for the tooth loss (Shimazaki 
et al 2001; Stein et al 2007), although none has established 
periodontal disease per se as the risk factor for dementia. 
Next, PDD must be correlated with AD. A few studies 
have suggested this is to be the case (eg, Kondo et al 1994; 
Gatz et al 2006; Stein et al 2007) although tooth loss was 
used as the index of PDD in these studies. Finally, all 
other possible contributors must be controlled for. While 
this is not entirely possible, steps have been and could be 
taken to account for some potential contributing factors. 
This includes external factors that might contribute to both 
tooth loss and dementia separately such as viral infection 
in different body systems, head injury, low socioeconomic 
status, malnutrition, or an exaggerated inﬂ  ammatory pro-
ﬁ  le. Eventually, randomized-controlled intervention trials 
with a long follow-up period would be needed to establish Neuropsychiatric Disease and Treatment 2008:4(5) 873
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whether preventive oral health measures could reduce the 
risk of AD.
For inﬂ  ammation to be clearly established as a mediator 
for the relationship between PDD and dementia, it should 
be present in both oral disease and dementia as has been 
demonstrated through several studies (Licastro et al 1995; 
Singh and Guthikonda 1997; Loos 2005). Treating PDD 
should reduce inﬂ  ammation (Ebersole et al 1997; Mattila et al 
2002; D’Aiuto et al 2004; Taylor et al 2006) and reducing 
inﬂ  ammation should lead to reduced incidence of dementia. 
Epidemiological studies suggest that nonsteroidal antiinﬂ  am-
matory drugs (NSAIDs) may protect against the development 
of AD if taken in midlife, many years prior to the diagnosis 
of dementia (eg, Hayden et al 2007). However, evidence 
from epidemiological studies, fundamental pathology, and 
clinical trials suggest that COX-2 inhibitors fail to reduce AD 
pathology and have not been shown to be effective in indi-
viduals who have already developed dementia (Townsend 
and Pratico 2005; McGeer and McGeer 2007).
No published studies have measured inflammation 
concurrently with PDD and dementia to allow a determina-
tion of its role in the relationship. It is necessary to determine 
whether inﬂ  ammatory processes in the brain are initiated or 
exacerbated by systemic infection and inﬂ  ammation resulting 
from PDD, or whether they reﬂ  ect completely independent 
sources (eg, immune response to AD pathology).
Conclusion
This review and synthesis of the association between 
PDD and AD integrates research from disparate ﬁ  elds. 
Despite evidence that oral disease may be a risk factor for 
dementia, little attention has been devoted to explaining 
the potential mechanisms for this association (see Stein 
et al 2006). We propose that bacterial and viral infections 
commonly found in PDD may impact the brain, either 
directly or via systemic signals to the brain, and contribute 
to the development of AD. Periodontal infections may 
result in harmful pathogenic products leading to systemic 
inﬂ  ammatory responses. Elevated systemic inﬂ  ammatory 
response may contribute to the exacerbation of existing 
brain pathologies. Infections may also contribute to vascu-
lar pathology with the potential to impact brain function. 
PDD and AD may also share common risk factors such 
as genetic polymorphisms related to production of inﬂ  am-
matory mediators.
Though there are theoretical reasons for suspecting that 
pathogens may play a role in AD, controversy remains 
given the mixed results of post-mortem brain studies 
(Kinoshita 2004). Further evidence is needed to determine 
whether pathogens contribute uniquely to AD or are involved 
in a common cause. For example, perhaps those carrying the 
APOE ε4 allele may have a hyperinﬂ  ammatory response to 
challenges from pathogen products or be highly vulnerable 
to infection.
Few studies have attempted to link oral health with AD 
diagnosis or disease pathology and none have investigated 
the role of inﬂ  ammation as a potential mediator. Information 
about history of chronic infection among AD patient popula-
tions would help to investigate this hypothesis. Longitudinal 
data measuring periodontal status, levels of inﬂ  ammatory 
markers, and cognitive status would be ideal.
If systemic infection and inﬂ  ammation prove to be con-
tributors to AD, several preventive measures and treatment 
strategies would be implied. Such developments may be 
particularly signiﬁ  cant given the paucity of promising pre-
ventative strategies for AD at the present time. Focus on the 
prevention of oral and other sources of systemic infection 
would be warranted. Timely treatment of periodontal infec-
tion might be indicated to reduce risk of systemic infection 
and inﬂ  ammation. Though successful treatment of PDD has 
shown reductions in inﬂ  ammation (eg, Taylor et al 2006), 
it remains to be determined whether this would reduce risk 
of CVD or dementia. Identiﬁ  cation of individuals suscep-
tible to infection and hyperinﬂ  ammation would allow for 
targeted prevention to reduce contact with pathogens and 
treatment strategies to reduce harm from hyperinﬂ  amma-
tory incidents.
The model presented here should enable researchers to 
test speciﬁ  c hypotheses regarding the multiple inter-related 
mechanisms that may be responsible for an association 
between oral infection, inﬂ  ammation, and the development 
of Alzheimer pathology. In particular, research should 
examine whether pathogen products and inﬂ  ammation 
resulting from periodontal infection are related to these 
same processes suspected to contribute to pathology in 
AD or whether the two diseases merely share common 
risk factors.
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